Literature DB >> 25037800

Cutaneous reactions to chemotherapeutic drugs and targeted therapies for cancer: part I. Conventional chemotherapeutic drugs.

Claire Marie Reyes-Habito1, Ellen K Roh2.   

Abstract

Conventional chemotherapy continues to be an important part of cancer management, but may cause various cutaneous reactions because it disturbs specific cell cycle phases. The alkylating agents cyclophosphamide, ifosfamide, and thiotepa can produce hyperpigmentation, while hypersensitivity reactions can be seen with platinum alkylating agents. Antimetabolites vary in reactions from exanthematous to bullous skin lesions. 5-fluorouracil and its derivatives and liposomal doxorubicin and daunorubicin are characteristically known to cause hand-foot syndrome, while bleomycin can cause fibrosis and flagellate dermatitis. Several hypersensitivity reactions may also occur from mitotic inhibitors and topoisomerase inhibitors. These different characteristic presentations are important to dermatologists in identifying the correct diagnosis and management for the cancer patient.
Copyright © 2014 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.

Entities:  

Keywords:  cancer; chemotherapy; cutaneous reactions; cytotoxic therapy; drug hypersensitivity; rash

Mesh:

Substances:

Year:  2014        PMID: 25037800     DOI: 10.1016/j.jaad.2014.04.014

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  11 in total

1.  Chemotherapy reaction induced by ixabepilone, a microtubule stabilizing agent, mimicking extramammary Paget's disease in a patient with breast carcinoma.

Authors:  Jillian W Millsop; Victoria R Sharon; Tatyana Petukhova; Maxwell A Fung; Maija Kiuru
Journal:  J Cutan Pathol       Date:  2016-10-24       Impact factor: 1.587

2.  Liposomal cytarabine and daunorubicin (CPX-351/Vyxeos)-associated distinct purpuric subtype of toxic erythema of chemotherapy: A retrospective review of 54 patients.

Authors:  Joseph R Stoll; Laura Battle; Andrea Moy; Stephen W Dusza; Jae H Park; Martin S Tallman; Justin Taylor; Alina Markova
Journal:  J Am Acad Dermatol       Date:  2021-02-02       Impact factor: 15.487

3.  Paclitaxel-associated reticulate hyperpigmentation: Report and review of chemotherapy-induced reticulate hyperpigmentation.

Authors:  Philip R Cohen
Journal:  World J Clin Cases       Date:  2016-12-16       Impact factor: 1.337

Review 4.  Cutaneous complications of molecular targeted therapy used in oncology.

Authors:  I Lupu; N Voiculescu; N Bacalbasa; I Cojocaru; V Vrancian; C Giurcaneanu
Journal:  J Med Life       Date:  2016 Jan-Mar

5.  Unusual progression of renal cell carcinoma with carcinomatosis peritoneii and Krukenberg tumour and alopecia with sunitinib therapy in young female.

Authors:  Manoj Pandey; Mahendran Ramasamy; Mridula Shukla
Journal:  World J Surg Oncol       Date:  2018-02-06       Impact factor: 2.754

6.  A technical appraisal of guidelines for the management of skin rash in patients on chemotherapy and targeted therapy.

Authors:  Fangyuan Zhang; Sumei Lv; Yating Feng; Xuan Yang; Wanmin Qiang
Journal:  BMC Health Serv Res       Date:  2019-10-16       Impact factor: 2.655

Review 7.  Management of dermatologic adverse events from cancer therapies: recommendations of an expert panel.

Authors:  Jade Cury-Martins; Adriana Pessoa Mendes Eris; Cristina Martinez Zugaib Abdalla; Giselle de Barros Silva; Veronica Paula Torel de Moura; Jose Antonio Sanches
Journal:  An Bras Dermatol       Date:  2020-02-15       Impact factor: 1.896

8.  Evaluation of cutaneous side-effects associated with chemotherapeutic use in oncological patients.

Authors:  Zeynep Utlu; Handan Bilen
Journal:  Postepy Dermatol Alergol       Date:  2021-10-22       Impact factor: 1.837

9.  Recurrent Body Rash Warranted Second Desensitization With Acyclovir in a Myeloma Patient: A Case Report.

Authors:  Jack T Seki; Pamela Ng; Wallace Lam; Julie Cote; Anca Prica
Journal:  J Clin Med Res       Date:  2017-07-01

Review 10.  Evolution from small molecule to nano-drug delivery systems: An emerging approach for cancer therapy of ursolic acid.

Authors:  Jingwei Shao; Yifan Fang; Ruirui Zhao; Fangmin Chen; Mingyue Yang; Jiali Jiang; Zixuan Chen; Xiaotian Yuan; Lee Jia
Journal:  Asian J Pharm Sci       Date:  2020-03-21       Impact factor: 6.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.